Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06BUA
|
|||
| Former ID |
DIB002912
|
|||
| Drug Name |
Nexopamil
|
|||
| Synonyms |
LU-49938
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 2 | [1] | |
| Company |
BASF AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H40N2O3
|
|||
| Canonical SMILES |
CCCCCCN(C)CCCC(C#N)(C1=CC(=C(C(=C1)OC)OC)OC)C(C)C
|
|||
| InChI |
1S/C24H40N2O3/c1-8-9-10-11-14-26(4)15-12-13-24(18-25,19(2)3)20-16-21(27-5)23(29-7)22(17-20)28-6/h16-17,19H,8-15H2,1-7H3/t24-/m0/s1
|
|||
| InChIKey |
SKDZEFVVFACNLS-DEOSSOPVSA-N
|
|||
| CAS Number |
CAS 136033-49-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2 receptor (5HT2R) | Target Info | Modulator | [1] |
| Calcium channel unspecific (CaC) | Target Info | Blocker | [1] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.